Companies Orasure Technologies Inc
Orasure Technologies (OSUR): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Orasure Technologies Inc’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers50th pct.Of 20 peer CEOs
CEO pay, last three years
- $6,701,767FY2023
- $5,602,298FY2024
- $4,292,228FY2025
CEO total pay was $4,292,228 in fiscal 2025, down from $5,602,298 in fiscal 2024.
FY2025: salary $721,000 · bonus $0 · stock awards $3,394,188 · option awards $0
Executives and directors
Carrie Eglinton Manner · CEOKathleen Weber · Chief Product OfficerKenneth McGrath · CFODavid J. Shulkin · Independent DirectorJohn D. Bertrand · Independent DirectorJohn P. Kenny · Chair of the BoardLelio Marmora · Independent DirectorMara G. Aspinall · Former director (through FY2025)Nancy J. Gagliano · Independent DirectorRobert W. McMahon · Independent DirectorSteven K. Boyd · Independent Director
Frequently asked questions
Who was the highest-paid executive at Orasure Technologies Inc in fiscal 2025?
As disclosed, Carrie Eglinton Manner (President and Chief Executive Officer) was the highest-paid executive at Orasure Technologies Inc in fiscal 2025, with total compensation of $4,292,228.
How does Orasure Technologies Inc's chief executive pay compare to its disclosed peer group?
As disclosed, Carrie Eglinton Manner's total compensation ranked at the 50th percentile of Orasure Technologies Inc's disclosed peer group.
What is Orasure Technologies Inc's CEO-to-median employee pay ratio?
As disclosed, Orasure Technologies Inc's CEO-to-median employee pay ratio was 54:1.
How did shareholders vote on Orasure Technologies Inc's executive compensation?
As disclosed, 87.87% of shareholders supported Orasure Technologies Inc's executive compensation in the latest say-on-pay vote.
How much does Orasure Technologies Inc spend in total on board compensation for fiscal 2025?
As disclosed, Orasure Technologies Inc reported total board compensation of $1,680,430 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Carrie Eglinton Manner | $721,000 | $0 | $3,394,188 | $0 | $173,040 | $0 | $4,000 | $4,292,228 |
| President and Chief Executive Officer | ||||||||
| Kathleen Weber | 421,145 | 0 | 647,020 | 0 | 0 | 0 | 768,270 | 1,836,435 |
| Former Chief Product Officer | ||||||||
| Kenneth McGrath | 512,000 | 0 | 738,768 | 0 | 61,440 | 0 | 4,000 | 1,316,208 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Carrie Eglinton Manner | $4,292,228 | $5,602,298 | $6,701,767 | ↓ −1,310,070 |
| Kathleen Weber | 1,836,435 | 1,397,738 | 1,672,897 | ↑ +438,697 |
| Kenneth McGrath | 1,316,208 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The Company's compensation program is performance-based and is designed to pay executives for performance by offering rewards for the achievement of pre-determined objectives. It is designed to align the interests of executives with those of stockholders, provide long-term incentives, and set compensation at levels sufficiently competitive to attract, retain, and motivate high-quality executives.
| CEO STI target (% of salary) | 100% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pay Governance |
| Clawback policy | true |
| Anti-hedging | True |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Kenneth McGrath | RSU | 2025-03-01 | — | — | 100,647 | — | $348,249 |
| Carrie Eglinton Manner | PSU | 2025-03-01 | 231,207 | 462,414 | — | 693,621 | 1,988,380 |
| Kathleen Weber | RSU | 2025-03-01 | — | — | 88,148 | — | 305,001 |
| Carrie Eglinton Manner | RSU | 2025-03-01 | — | — | 462,414 | — | 1,599,999 |
| Kenneth McGrath | PSU | 2025-03-01 | 50,324 | 100,648 | — | 150,972 | 432,786 |
| Kathleen Weber | PSU | 2025-03-01 | 44,074 | 88,148 | — | 132,221 | 379,036 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Kenneth McGrath | $348,249 | $432,786 | $0 | 55.4% |
| Carrie Eglinton Manner | 1,599,999 | 1,988,380 | 0 | 55.4% |
| Kathleen Weber | 305,001 | 379,036 | 0 | 55.4% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Kenneth McGrath | RSU | 17,876 | — | $43,260 |
| Kenneth McGrath | PSU | 26,815 | — | 64,891 |
| Kenneth McGrath | RSU | 39,173 | — | 94,799 |
| Kenneth McGrath | PSU | 58,759 | — | 71,098 |
| Carrie Eglinton Manner | RSU | 86,022 | — | 208,173 |
| Kenneth McGrath | RSU | 100,647 | — | 243,566 |
| Kenneth McGrath | PSU | 100,648 | — | 243,568 |
| Carrie Eglinton Manner | PSU | 129,033 | — | 312,259 |
| Carrie Eglinton Manner | RSU | 173,792 | — | 420,577 |
| Carrie Eglinton Manner | PSU | 260,688 | — | 315,432 |
| Carrie Eglinton Manner | RSU | 462,414 | — | 1,119,042 |
| Carrie Eglinton Manner | PSU | 462,414 | — | 1,119,042 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Mara G. AspinallIndependent · Audit · Departed during FY | $92,942 | $184,996 | $0 | $0 | $0 | $277,938 |
| Nancy J. GaglianoIndependent · Compensation (Chair) · Nominating and Corporate Governance (Chair) | 82,631 | 184,996 | 0 | 0 | 0 | 267,627 |
| John P. KennyIndependent · Board Chair · Compensation | 82,433 | 184,996 | 0 | 0 | 0 | 267,429 |
| Robert W. McMahonIndependent · Audit (Chair) | 75,000 | 184,996 | 0 | 0 | 0 | 259,996 |
| Lelio MarmoraIndependent · Audit · Nominating and Corporate Governance | 65,000 | 184,996 | 0 | 0 | 0 | 249,996 |
| David J. ShulkinIndependent · Compensation | 61,080 | 184,996 | 0 | 0 | 0 | 246,076 |
| Steven K. BoydIndependent · Audit · Nominating and Corporate Governance | 11,368 | 100,000 | 0 | 0 | 0 | 111,368 |
| John D. BertrandIndependent · Nominating and Corporate Governance · Newly elected | 0 | 0 | 0 | 0 | 0 | 0 |
| Carrie Eglinton MannerEmployee director | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $55,000 |
|---|---|
| Annual equity retainer | $185,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 20,000 / 20,000 |
| Stock ownership guideline | The internal controls and procedures in place to mitigate risks facing the Company, including the Company’s “clawback” policy and stock ownership guidelines; |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $470,454 |
| Equity awards (grant-date value) | $1,209,976 |
| All other compensation | $0 |
| Total cost of the board | $1,680,430 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Orasure Technologies as a peer
Companies that benchmark against OSUR
14 companies name OSUR as a compensation peer
The list of companies that name OSUR as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
CERS Cerus CorporationALPH Alpha Teknova, Inc.CDXS Codexis, Inc.PSNL Personalis, Inc.BDSX Biodesix, Inc.BIOA BioLife Solutions, Inc.CSL Castle Biosciences, Inc.FLGT Fulgent Genetics, Inc.HRVS Harvard Bioscience, Inc.LFCR Lifecore Biomedical, Inc.QTRX Quanterix CorporationLAB Standard BioTools Inc.TCMD Tactile Systems Technology, Inc.CYTX Cytek Biosciences, Inc.EXGN Exagen Inc.CYRX Cryoport, Inc.MRVI Maravai LifeSciences, Inc.PACB Pacific Biosciences of California, Inc.ANGO AngioDynamics, Inc.MLAB Mesa Laboratories, Inc.
Peer reciprocity
The companies Orasure Technologies Inc names as compensation peers that name it back in their own disclosed peer groups.
Cerus Corporation (CERS)59Personalis, Inc. (PSNL)60Lifecore Biomedical, Inc. (LFCR)61Standard BioTools Inc. (LAB)62
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Castle Biosciences, Inc. | 2025 | D. Christian Koch | $1,493,000 | $6,376,929 | $2,612,603 | $0 | $11,359,438 |
| 2 | Maravai LifeSciences, Inc. | 2025 | Bernd Brust | 388,863 | 7,660,000 | 1,460,000 | 425,343 | 10,129,708 |
| 3 | Standard BioTools Inc. | 2025 | Michael Egholm | 680,256 | 5,337,883 | 1,671,363 | 1,120,000 | 8,823,502 |
| 4 | Mesa Laboratories, Inc. | 2026 | Gary Owens | 808,846 | 4,700,017 | 0 | 1,120,000 | 6,643,208 |
| 5 | Fulgent Genetics, Inc. | 2025 | Ming Hsieh | 1,000,000 | 4,000,000 | 0 | 1,207,000 | 6,207,000 |
| 6 | AngioDynamics, Inc. | 2026 | James Clemmer | 828,171 | 3,689,866 | 0 | 1,502,491 | 6,060,145 |
| 7 | Quanterix Corporation | 2025 | Masoud Toloue | 670,950 | 1,170,000 | 2,729,998 | 674,172 | 5,250,745 |
| 8 | Pacific Biosciences of California, Inc. | 2025 | Christian Henry | 748,250 | 1,151,013 | 1,696,278 | 714,305 | 4,309,846 |
| 9 | Orasure Technologies Inc | 2025 | Carrie Eglinton Manner | 721,000 | 3,394,188 | 0 | 173,040 | 4,292,228 |
| 10 | Cerus Corporation | 2025 | William Greenman | 793,750 | 2,242,585 | 0 | 756,000 | 3,794,657 |
| 11 | Personalis, Inc. | 2025 | Christopher Hall | 618,000 | 853,050 | 1,784,728 | 247,200 | 3,505,978 |
| 12 | Tactile Systems Technology, Inc. | 2025 | Sheri Dodd | 675,000 | 2,019,978 | 0 | 737,438 | 3,466,916 |
| 13 | BioLife Solutions, Inc. | 2025 | Kristen Fortney | 600,000 | 0 | 1,941,390 | 330,000 | 2,886,590 |
| 14 | Cryoport, Inc. | 2025 | Jerrell Shelton | 967,845 | 192,300 | 306,869 | 908,510 | 2,375,524 |
| 15 | Codexis, Inc. | 2025 | Alison Moore | 524,732 | 255,994 | 1,065,223 | 463,125 | 2,323,279 |
| 16 | Biodesix, Inc. | 2025 | Scott Hutton | 643,404 | 356,849 | 524,437 | 710,280 | 2,238,470 |
| 17 | Lifecore Biomedical, Inc. | 2025 | Paul Josephs | 550,000 | 274,996 | — | — | 1,115,305 |
| — | Alpha Teknova, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Harvard Bioscience, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Cytek Biosciences, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Exagen Inc. | — | — | — | — | — | — | not in coverage universe |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Orasure Technologies Inc | 24.0% | RSU 50 · PSU 50 | Yes — Relative TSR performance vs peer group | Pay Governance |
| Alpha Teknova, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| AngioDynamics, Inc. | 180% | PSU 50 · RSU 50 | No | Meridian Compensation Partners, LLC |
| Biodesix, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| BioLife Solutions, Inc. | not disclosed | Option 100 | not disclosed | Alpine Rewards LLC |
| Castle Biosciences, Inc. | not disclosed | PSU 33 · RSU 33 · Options 33 | No | Willis Towers Watson |
| Cerus Corporation | 126% | not disclosed | No | Alpine |
| Codexis, Inc. | 95% | not disclosed | not disclosed | Pearl Meyer |
| Cryoport, Inc. | 92.2% | not disclosed | not disclosed | Frederic W. Cook & Co., Inc. |
| Cytek Biosciences, Inc. | not disclosed | Option 50 · RSU 50 | not disclosed | Meridian Compensation Partners, LLC |
| Exagen Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Fulgent Genetics, Inc. | 120.7% | PSU 60 · RSU 40 | No | USI |
| Harvard Bioscience, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Lifecore Biomedical, Inc. | not disclosed | not disclosed | not disclosed | Frederic W. Cook & Co. |
| Maravai LifeSciences, Inc. | not disclosed | not disclosed | No | Meridian Compensation Partners, LLC |
| Mesa Laboratories, Inc. | 125% | PSU 50 · RSU 50 | No | Frederic W. Cook & Co, Inc. |
| Pacific Biosciences of California, Inc. | 95% | not disclosed | not disclosed | Aon Human Capital Solutions |
| Personalis, Inc. | not disclosed | not disclosed | not disclosed | Aon |
| Quanterix Corporation | 95% | Options 70 · RSU 30 | not disclosed | PayGov |
| Standard BioTools Inc. | 160% | not disclosed | not disclosed | Pearl Meyer |
| Tactile Systems Technology, Inc. | 115% | PSU 50 · RSU 50 | No | Aon Consulting, Inc. |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-03 | 45,225,131 | 6,179,090 | 62,939 | 87.87% | Passed |
| 2025 | 2025-05-14 | 51,997,355 | 6,477,192 | 203,773 | 88.61% | Passed |
| 2024 | 2024-05-14 | 57,538,779 | 4,472,675 | 111,471 | 92.62% | Passed |
| 2023 | 2023-05-16 | 39,391,642 | 20,030,810 | 69,297 | 66.21% | Passed |
| 2022 | 2022-05-17 | 56,687,157 | 1,535,739 | 113,706 | 97.36% | Passed |
| 2021 | 2021-05-18 | 50,490,819 | 2,320,406 | 386,653 | 95.61% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-03 | 87.87%a |
| 2025 | 2025-05-14 | 88.61%b |
| 2024 | 2024-05-14 | 92.62%c |
a. Approved under the standard stated in the filing — “Abstentions will have the effect of a vote "against" the outcome of this proposal, and broker non-votes, if any, will have no effect on the outcome of this proposal.”.
b. Approved under the standard stated in the filing — “Abstentions will have the effect of voting against this proposal.”.
c. Approved under the standard stated in the filing — “Abstentions will have the effect of voting against this proposal.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 54 : 1 |
|---|---|
| CEO total compensation | $4,292,228 |
| Median employee compensation | $79,397 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| John D. Bertrand | Director | 2026-05-12 | A | 33,661 | $0 | $0 | Common | Form 4 ↗ |
| Steven K. Boyd | Director | 2026-05-12 | A | 25,000 | 3 | 74,500 | Common | Form 4 ↗ |
| Robert W. McMahon | Director | 2026-05-13 | D | 22,888 | 3 | 69,122 | Common | Form 4 ↗ |
| Nancy J. Gagliano | Director | 2026-05-13 | D | 21,305 | 3 | 64,341 | Common | Form 4 ↗ |
| Lelio Marmora | Director | 2026-05-13 | D | 28,406 | 3 | 85,786 | Common | Form 4 ↗ |
| Steven K. Boyd | Director | 2026-05-13 | A | 25,000 | 3 | 75,500 | Common | Form 4 ↗ |
| Steven K. Boyd | Director | 2026-05-14 | A | 25,000 | 3 | 74,750 | Common | Form 4 ↗ |
| John D. Bertrand | Director | 2026-06-03 | A | 46,106 | 0 | 0 | Common | Form 4 ↗ |
| Lelio Marmora | Director | 2026-06-03 | A | 46,106 | 0 | 0 | Common | Form 4 ↗ |
| Robert W. McMahon | Director | 2026-06-03 | A | 46,106 | 0 | 0 | Common | Form 4 ↗ |
| Nancy J. Gagliano | Director | 2026-06-03 | A | 46,106 | 0 | 0 | Common | Form 4 ↗ |
| John P. Kenny | Director | 2026-06-03 | A | 46,106 | 0 | 0 | Common | Form 4 ↗ |
| Steven K. Boyd | Director | 2026-06-03 | A | 46,106 | 0 | 0 | Common | Form 4 ↗ |
| Steven K. Boyd | Director | 2026-06-26 | A | 3,666 | 4 | 16,250 | Common | Form 4 ↗ |
| John P. Kenny | Director | 2026-09-06 | D | 5,116 | 3 | 17,535 | Common | Form 4 ↗ |
| Steven K. Boyd | Director | 2026-09-29 | A | 4,797 | 4 | 18,612 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (62 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Carrie Eglinton Manner. DEF 14A, filed 2026-04-30. Section “SUMMARY COMPENSATION TABLE” · page 56. As printed: 4,292,228. View filing ↗
- Section 01, Kathleen Weber. DEF 14A, filed 2026-04-30. Section “SUMMARY COMPENSATION TABLE” · page 55. As printed: 1,836,435. View filing ↗
- Section 01, Kenneth McGrath. DEF 14A, filed 2026-04-30. Section “SUMMARY COMPENSATION TABLE” · page 55. As printed: 1,316,208. View filing ↗
- Section 03, Kenneth McGrath RSU. DEF 14A, filed 2026-04-30. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Carrie Eglinton Manner PSU. DEF 14A, filed 2026-04-30. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Kathleen Weber RSU. DEF 14A, filed 2026-04-30. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Carrie Eglinton Manner RSU. DEF 14A, filed 2026-04-30. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Kenneth McGrath PSU. DEF 14A, filed 2026-04-30. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Kathleen Weber PSU. DEF 14A, filed 2026-04-30. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-30. Section “CEO Pay Ratio”. As printed: 54 : 1. View filing ↗
- Section 08, Mara G. Aspinall. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 277,938. View filing ↗
- Section 08, Nancy J. Gagliano. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 267,627. View filing ↗
- Section 08, John P. Kenny. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 267,429. View filing ↗
- Section 08, Robert W. McMahon. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 259,996. View filing ↗
- Section 08, Lelio Marmora. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 249,996. View filing ↗
- Section 08, David J. Shulkin. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 246,076. View filing ↗
- Section 08, Steven K. Boyd. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 111,368. View filing ↗
- Section 08, John D. Bertrand. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Carrie Eglinton Manner. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, John D. Bertrand 2026-05-12. Form 4, filed 2026-05-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven K. Boyd 2026-05-12. Form 4, filed 2026-05-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert W. McMahon 2026-05-13. Form 4, filed 2026-05-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nancy J. Gagliano 2026-05-13. Form 4, filed 2026-05-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lelio Marmora 2026-05-13. Form 4, filed 2026-05-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven K. Boyd 2026-05-13. Form 4, filed 2026-05-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven K. Boyd 2026-05-14. Form 4, filed 2026-05-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John D. Bertrand 2026-06-03. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lelio Marmora 2026-06-03. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert W. McMahon 2026-06-03. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nancy J. Gagliano 2026-06-03. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John P. Kenny 2026-06-03. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven K. Boyd 2026-06-03. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven K. Boyd 2026-06-26. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John P. Kenny 2026-09-06. Form 4, filed 2026-09-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven K. Boyd 2026-09-29. Form 4, filed 2026-10-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-03. Item 5.07 · say-on-pay result. As reported: 87.87% (votes for as printed: 45,225,131). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-05-14. Item 5.07 · say-on-pay result. As reported: 88.61% (votes for as printed: 51,997,355). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-05-17. Item 5.07 · say-on-pay result. As reported: 92.62% (votes for as printed: 57,538,779). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 470,454 + equity 1,209,976 + all other 0 = 1,680,430, summed across the director compensation table rows.
- Castle Biosciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-17. CEO total compensation as printed in Castle Biosciences, Inc.'s own proxy. As printed: 11,359,438. View filing ↗
- Maravai LifeSciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Maravai LifeSciences, Inc.'s own proxy. As printed: 10,129,708. View filing ↗
- Standard BioTools Inc., Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Standard BioTools Inc.'s own proxy. As printed: 8,823,502. View filing ↗
- Mesa Laboratories, Inc., Section 10b CEO total. DEF 14A, filed 2026-07-22. CEO total compensation as printed in Mesa Laboratories, Inc.'s own proxy. As printed: 6,643,208. View filing ↗
- Fulgent Genetics, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-31. CEO total compensation as printed in Fulgent Genetics, Inc.'s own proxy. As printed: 6,207,000. View filing ↗
- AngioDynamics, Inc., Section 10b CEO total. DEF 14A, filed 2026-10-08. CEO total compensation as printed in AngioDynamics, Inc.'s own proxy. As printed: 6,060,145. View filing ↗
- Quanterix Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Quanterix Corporation's own proxy. As printed: 5,250,745. View filing ↗
- Pacific Biosciences of California, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Pacific Biosciences of California, Inc.'s own proxy. As printed: 4,309,846. View filing ↗
- Orasure Technologies Inc (subject), Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Orasure Technologies Inc's own proxy. As printed: 4,292,228. View filing ↗
- Cerus Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Cerus Corporation's own proxy. As printed: 3,794,657. View filing ↗
- Personalis, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-02. CEO total compensation as printed in Personalis, Inc.'s own proxy. As printed: 3,505,978. View filing ↗
- Tactile Systems Technology, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-25. CEO total compensation as printed in Tactile Systems Technology, Inc.'s own proxy. As printed: 3,466,916. View filing ↗
- BioLife Solutions, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in BioLife Solutions, Inc.'s own proxy. As printed: 2,886,590. View filing ↗
- Cryoport, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Cryoport, Inc.'s own proxy. As printed: 2,375,524. View filing ↗
- Codexis, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Codexis, Inc.'s own proxy. As printed: 2,323,279. View filing ↗
- Biodesix, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-09. CEO total compensation as printed in Biodesix, Inc.'s own proxy. As printed: 2,238,470. View filing ↗
- Lifecore Biomedical, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Lifecore Biomedical, Inc.'s own proxy. As printed: 1,115,305. View filing ↗
- Section 10a, Cerus Corporation reciprocity. DEF 14A. Cerus Corporation names Orasure Technologies Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Personalis, Inc. reciprocity. DEF 14A. Personalis, Inc. names Orasure Technologies Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Lifecore Biomedical, Inc. reciprocity. DEF 14A. Lifecore Biomedical, Inc. names Orasure Technologies Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Standard BioTools Inc. reciprocity. DEF 14A. Standard BioTools Inc. names Orasure Technologies Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗